Assertio therapeutics news
Here are some recent news articles and updates about Assertio Therapeutics:
Recent News
- Assertio Therapeutics Announces FDA Approval of Gralise (gabapentin) for the Management of Postherpetic Neuralgia (February 2023)
Assertio Therapeutics, a biopharmaceutical company, announced that the FDA has approved Gralise (gabapentin) for the management of postherpetic neuralgia (PHN), a chronic pain condition caused by shingles.
- Assertio Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (February 2023)
The company reported its financial results for the fourth quarter and full year 2022, including a net loss of $14.4 million for the quarter and a net loss of $54.1 million for the year.
- Assertio Therapeutics Presents Data on Gralise (gabapentin) for the Management of Postherpetic Neuralgia at the 2022 American Academy of Pain Medicine Annual Meeting (March 2022)
The company presented data on Gralise for the management of PHN at the American Academy of Pain Medicine Annual Meeting, highlighting the medication's efficacy and safety in treating chronic pain.
Recent Developments
- Assertio Therapeutics Expands Commercial Operations to Support Growing Product Portfolio (January 2023)
The company announced the expansion of its commercial operations to support the growth of its product portfolio, including Gralise and other medications.
- Assertio Therapeutics Enters into Partnership with Aeterna Zentaris to Develop and Commercialize Macrilen (macimorelin) in the United States (December 2022)
The company entered into a partnership with Aeterna Zentaris to develop and commercialize Macrilen, a medication for the diagnosis of adult growth hormone deficiency, in the United States.
- Assertio Therapeutics Appoints New Chief Commercial Officer (November 2022)
The company appointed a new Chief Commercial Officer to lead its commercial operations and drive growth of its product portfolio.
Please note that these news articles and updates are subject to change and may not reflect the company's current status or developments.